ClinicalTrials.gg
RecruitingNCT07409649HI-LOOPUpdated Nov 20, 2026

Influence of Intermittent Hypoxia on Loop Gain in Healthy Subjects

An interventional study of Intermittent hypoxia and Normoxia in Intermittent Hypoxia and Healthy Volunteers, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Prevention

How we know

Updated Nov 20, 2026Now RecruitingStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Hypoxia with a site in France — 17 open to participants now, 17 under way, 1 of them phase 3. Hypoxia · France.

Planned enrollment
26th of 51
40 · median 40
Started
2026
with 4 others
No phase
37 of 72
12 open now
Primary completion
2027-12
later than 11 of 16 live
Registered
67th of 72
by date
Lead sponsor
4 of 72
Poitiers University Hospital

Among the 72 studies in Hypoxia with a site in France, this one is the 26th largest by planned enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2026, is one of 37 with no phase, reaches primary completion later than 11 of the 16 other live ones, and was the 67th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

17 of the 72 studies in Hypoxia with a site in France are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Hypoxia with a site in France, or all of them as a file.
02

Study summary

Sleep apnoea-hypopnoea syndrome (SAHOS), which causes numerous comorbidities, particularly cardiovascular ones, is widespread worldwide today and incurs significant healthcare costs.

Current research in this field focuses on identifying different phenotypes in affected patients in order to provide more personalised treatment.

One of these phenotypes appears to be linked to instability in ventilatory control due to an increase in loop gain (LG) in these subjects.

However, the pathophysiology of this ventilatory control instability due to increased LG is not fully understood. It is still difficult to determine whether subjects have an intrinsically high LG or if exposure to intermittent hypoxia during OSA promotes an increase in LG.

It has also been demonstrated that OSA causes vascular hyperreactivity by increasing oxidative stress through elevated ROS production. This leads to endothelial dysfunction in response to intermittent hypoxia associated with apnoea. Extracellular vesicles (microvesicles and exosomes) have been shown to play a role in this endothelial response. These extracellular vesicles are essential for intercellular communication in both physiological and pathological situations, such as SAHOS.

Therefore, the objective of this research is to determine whether exposure to intermittent hypoxia and changes in microvesicle phenotype could influence LG, which could lead to new therapeutic advances in the context of SAHOS.

03

Conditions studied

  • Intermittent Hypoxia
  • Healthy Volunteers

Browse trials for

Keywords

  • loop gain
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy subjects aged 18 to 45
  • between [18-25] kg/m2
  • No known sleep disorders
  • Free subjects, not under guardianship or curatorship or subordination
  • Persons affiliated with or beneficiaries of a Social Security scheme
  • Signature of after clear and honest information about the study

Non-inclusion Criteria:

  • Active smoking or cessation within the last 3 months and total consumption > 10 pack-years
  • Alcohol or drug addiction
  • Excessive coffee consumption (> 3 espressos/day)
  • History of acute mountain sickness (presence of symptoms such as dizziness, headaches, nausea/vomiting, and incapacitating fatigue during or after a stay at high altitude)
  • Living at high altitude (above 3,000 meters, continuously for more than 6 months during the last 10 years)
  • History of respiratory and/or cardiovascular and/or renal and/or neurological disease (migraines, epilepsy)
  • Diabetes
  • Anemia, sickle cell anemia
  • Any medication associated with oxygen metabolism and any psychotropic medication (anxiolytics, sedatives, antidepressants, neuroleptics, muscle relaxants, etc.) that may interfere with motor and respiratory control, muscle strength, or sleep quality
  • Women of childbearing age who do not use effective (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy)
  • Concurrent participation in another clinical research study affecting respiratory control or respiratory muscles
  • Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, persons staying in a healthcare facility

Post-inclusion exclusion criteria:

  • SpO2 \< 97% in ambient air at rest.
  • Detection of pregnancy in women of childbearing age.
  • Detection of acute mountain sickness (Lake Louise score > 0).
  • Abnormalities in spirometry, ventilatory polygraphy, , and/or hemoglobinometry prior to randomization.
  • Ventilation minute signal, PETCO2 or PETO2 unusable.
  • Irreversible deterioration in the volunteer's health during the study period, likely to affect the experimental conditions.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm A : ambient air then intermittent hypoxia

    T1 : Conduct the experiment in ambient air (without hypoxia) for six hours. T2 : Then, after a washout period of at least seven days, conduct the experiment in intermittent hypoxia via the hypoxia chamber for six hours.

    Procedure: Intermittent hypoxia · Procedure: Normoxia

  • Experimental
    Arm B : intermittent hypoxia then ambient air

    T1 : Conduct an experiment involving intermittent hypoxia in the hypoxia chamber for six hours. T2 : Then, after a washout period of at least seven days, conduct an experiment involving ambient air (without hypoxia).

    Procedure: Intermittent hypoxia · Procedure: Normoxia

Interventions

  • ProcedureIntermittent hypoxia

    The volunteer will remain at rest in the hypoxic chamber, experiencing intermittent hypoxic conditions cyclically every 6 minutes. During one third of the cycle, they will be exposed to hypoxia in order to reduce SpO₂ to between 85% and 90%. Then, during two thirds of the cycle, they will receive oxygenation at a rate of 1 L/min (with possible subject-dependent modulations), with the aim of achieving an SpO₂ of greater than 95%. To make the hypoxia intermittent, the volunteer will also be given a medium-concentration oxygen mask that provides intermittent airflow, controlled by the D-6341 mass flow controller.

  • ProcedureNormoxia

    The participant will remain at rest in the hypoxic chamber under normoxic conditions. To prevent the volunteer from becoming aware of the conditions to which they are exposed, an air flow rate of 1 L/min will be used to simulate intermittent oxygenation.

06

What researchers measure

Primary outcomes

  1. The change in Loop Gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air).

    Loop gain is the product of 'controller gain' (ventilatory responsiveness to CO₂ above eupnoea) and 'plant gain' (the ventilatory increase required for a given reduction in PaCO₂). The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate). For each experimental condition (test-hypoxia or control-ambient air), loop gain will be measured before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber). The change in loop gain is defined as the difference between the average values (over 5 minutes) of the loop gain before and after the experimentation.

    Time frame: 6 hours of experimental condition

Secondary outcomes

  1. The change in controller gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)

    The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate). For each experimental condition (test-hypoxia or control-ambient air), controller gain will be assessed before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber). The change in controller gain is defined as the difference between the average values (over 5 minutes) of the controller gain before and after experimental condition.

    Time frame: 6 hours of experimental condition

  2. The change in plant gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)

    The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate). For each experimental condition (test-hypoxia or control-ambient air), plant gain will be assessed before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber). The change in plant gain is defined as the difference between the average values (over 5 minutes) of the plant gain before and after experimental condition.

    Time frame: 6 hours of experimental condition

  3. The change in the quantity of extracellular vesicles before and after 6 hours of experimental condition (intermittent hypoxia versus ambient air)

    The quantity of extracellular vesicles is assessed from blood samples using flow cytometry with specific antibodies. Blood samples are collected before the experimental condition (after 30 minutes of rest) and after the experimental condition (after leaving the hypoxic chamber). This change is expressed as the difference in the following extracellular vesicle concentrations before and after experimental conditioning: * EVs from platelets expressing CD41 * EVs from erythrocytes expressing CD235a * EVs from leukocytes expressing CD45 * EVs from endothelial cells expressing CD146 * EVs from granulocytes expressing CD66b and CD11b * EVs from activated leukocytes expressing CD62L * EVs from activated endothelial cells expressing CD62E * EVs from activated platelets expressing CD62P * CD62P/platelet ratio * EVs carrying the PSGL-1 ligand expressing CD162 * EVs carrying phosphatidylserine expressing annexin V

    Time frame: 6 hours of experimental condition

  4. Correlation between the change in quantity of extracellular vesicles and change in loop gain

    The change in the quantity of extracellular vesicles is defined as the difference of the extracellular vesicle concentration before and after the experimental condition (intermittent hypoxia and ambient air). The change in loop gain is defined as the difference of the loop gain values before and after the experimental condition (same definition as the primary outcome). We are interested in the following extracellular vesicles: CD41, CD235a, CD45, CD146, CD66b, CD11b, CD62L, CD62E, CD62P and CD62/platelet annexin V.

    Time frame: 6 hours of experimental condition

  5. Change in loop gain before and after experimental condition (intermittent hypoxia or ambient air), in the subgroup of patients with hyperventilation syndrome and in the subgroup of patients without hyperventilation syndrome.

    The change in loop gain is defined in the same way as the primary endpoint, i.e. as the difference between the measurements taken before and after the experimental condition. Hyperventilation syndrome is defined as a Nijmegen score of 23 or above at the inclusion visit.

    Time frame: 6 hours of experimental condition

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 14 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Jul 2026 → Oct 2026, primary completion Sep 2027 → Dec 2027 and completion Sep 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartEst.
Oct 20, 2026was Jul 2026
Primary completionEst.
Dec 2027was Sep 2027
CompletionEst.
Dec 2027was Sep 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
Poitiers University Hospital is now Recruiting
Oct 28, 2026
Start date
Jul 2026→Oct 20, 2026
Oct 28, 2026
Primary completion
Sep 2027→Dec 2027
Oct 28, 2026
Study completion
Sep 2027→Dec 2027
Oct 28, 2026
Eligibility
9 criteria added
What changed in the criteria
  • AddedInclusion Criteria:
  • AddedNon-inclusion Criteria:
  • AddedPost-inclusion exclusion criteria:
  • AddedSpO2 < 97% in ambient air at rest.
  • AddedDetection of pregnancy in women of childbearing age.
  • AddedDetection of acute mountain sickness (Lake Louise score > 0).
  • AddedAbnormalities in spirometry, ventilatory polygraphy, electrocardiogram, and/or hemoglobinometry prior to randomization.
  • AddedVentilation minute signal, PETCO2 or PETO2 unusable.
  • AddedIrreversible deterioration in the volunteer's health during the study period, likely to affect the experimental conditions.
Oct 28, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 28, 2026
  • ChangedBefore To evaluate the effect of intermittent hypoxia for 6 hours on the evolution of Loop GainNow The change in Loop Gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air).Time frame: through study completion (visit 1 and visit 2), an average of 14 months → after 6 hours of experimental condition
What changed on Nov 20, 2026
  • Time frameThe change in Loop Gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air).after 6 hours of experimental condition → 6 hours of experimental condition
across 2 updates, Oct 28, 2026 – Nov 20, 2026
Documents
across 2 updates, Oct 28, 2026 – Nov 20, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 28, 2026
  • EditedTo compare theThe change in the quantity of extracellular vesicles betweenbefore and after 6 hours of experimental conditions incondition (intermittent hypoxia andversus ambient air.)Time frame: through study completion (visit 1 and visit 2), an average of 14 months → after 6 hours of experimental condition
  • EditedTo compare changesChange in loop gain betweenbefore and after experimental conditions incondition (intermittent hypoxia andor ambient air), on the one hand in the subgroup of patients with hyperventilation syndrome and on the other hand in the subgroup of patients without hyperventilation syndrome.Time frame: through study completion (visit 1 and visit 2), an average of 14 months → after 6 hours of experimental condition
  • AddedThe change in controller gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)Time frame: after 6 hours of experimental condition
  • AddedThe change in plant gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)Time frame: after 6 hours of experimental condition
  • AddedCorrelation between the change in quantity of extracellular vesicles and change in loop gainTime frame: after 6 hours of experimental condition
  • RemovedTo compare the evolution of controller gain and plant gain between experimental conditions in hypoxia and ambient airTime frame: through study completion (visit 1 and visit 2), an average of 14 months
  • RemovedTo assess whether changes in the quantity of extracellular vesicles (and microvesicles) correlate with changes in loop gain, both under experimental conditions in hypoxia and under experimental conditions in ambient air.Time frame: through study completion (visit 1 and visit 2), an average of 14 months
What changed on Nov 20, 2026
  • Time frameThe change in controller gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)after 6 hours of experimental condition → 6 hours of experimental condition
  • Time frameThe change in plant gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)after 6 hours of experimental condition → 6 hours of experimental condition
  • Time frameThe change in the quantity of extracellular vesicles before and after 6 hours of experimental condition (intermittent hypoxia versus ambient air)after 6 hours of experimental condition → 6 hours of experimental condition
  • Time frameCorrelation between the change in quantity of extracellular vesicles and change in loop gainafter 6 hours of experimental condition → 6 hours of experimental condition
  • Time frameChange in loop gain before and after experimental condition (intermittent hypoxia or ambient air), in the subgroup of patients with hyperventilation syndrome and in the subgroup of patients without hyperventilation syndrome.after 6 hours of experimental condition → 6 hours of experimental condition
across 2 updates, Oct 28, 2026 – Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameThe change in Loop Gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air).after 6 hours of experimental condition → 6 hours of experimental condition
    Secondary outcomes 5 time frame changed
    What changed in the outcomes
    • Time frameThe change in controller gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)after 6 hours of experimental condition → 6 hours of experimental condition
    • Time frameThe change in plant gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)after 6 hours of experimental condition → 6 hours of experimental condition
    • Time frameThe change in the quantity of extracellular vesicles before and after 6 hours of experimental condition (intermittent hypoxia versus ambient air)after 6 hours of experimental condition → 6 hours of experimental condition
    • Time frameCorrelation between the change in quantity of extracellular vesicles and change in loop gainafter 6 hours of experimental condition → 6 hours of experimental condition
    • Time frameChange in loop gain before and after experimental condition (intermittent hypoxia or ambient air), in the subgroup of patients with hyperventilation syndrome and in the subgroup of patients without hyperventilation syndrome.after 6 hours of experimental condition → 6 hours of experimental condition
    + 1 other change: verification date
  2. Oct 28, 2026
    Not yet recruiting→Recruiting
    Poitiers University Hospital is now Recruiting
    Start date Jul 2026→Oct 20, 2026
    Primary completion Sep 2027→Dec 2027
    Study completion Sep 2027→Dec 2027
    Eligibility 9 criteria added
    What changed in the criteria
    • AddedInclusion Criteria:
    • AddedNon-inclusion Criteria:
    • AddedPost-inclusion exclusion criteria:
    • AddedSpO2 < 97% in ambient air at rest.
    • AddedDetection of pregnancy in women of childbearing age.
    • AddedDetection of acute mountain sickness (Lake Louise score > 0).
    • AddedAbnormalities in spirometry, ventilatory polygraphy, electrocardiogram, and/or hemoglobinometry prior to randomization.
    • AddedVentilation minute signal, PETCO2 or PETO2 unusable.
    • AddedIrreversible deterioration in the volunteer's health during the study period, likely to affect the experimental conditions.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore To evaluate the effect of intermittent hypoxia for 6 hours on the evolution of Loop GainNow The change in Loop Gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air).Time frame: through study completion (visit 1 and visit 2), an average of 14 months → after 6 hours of experimental condition
    Secondary outcomes 2 edited, 3 added, 2 removed
    What changed in the outcomes
    • EditedTo compare theThe change in the quantity of extracellular vesicles betweenbefore and after 6 hours of experimental conditions incondition (intermittent hypoxia andversus ambient air.)Time frame: through study completion (visit 1 and visit 2), an average of 14 months → after 6 hours of experimental condition
    • EditedTo compare changesChange in loop gain betweenbefore and after experimental conditions incondition (intermittent hypoxia andor ambient air), on the one hand in the subgroup of patients with hyperventilation syndrome and on the other hand in the subgroup of patients without hyperventilation syndrome.Time frame: through study completion (visit 1 and visit 2), an average of 14 months → after 6 hours of experimental condition
    • AddedThe change in controller gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)Time frame: after 6 hours of experimental condition
    • AddedThe change in plant gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)Time frame: after 6 hours of experimental condition
    • AddedCorrelation between the change in quantity of extracellular vesicles and change in loop gainTime frame: after 6 hours of experimental condition
    • RemovedTo compare the evolution of controller gain and plant gain between experimental conditions in hypoxia and ambient airTime frame: through study completion (visit 1 and visit 2), an average of 14 months
    • RemovedTo assess whether changes in the quantity of extracellular vesicles (and microvesicles) correlate with changes in loop gain, both under experimental conditions in hypoxia and under experimental conditions in ambient air.Time frame: through study completion (visit 1 and visit 2), an average of 14 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07409649
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Vanessa BIRONNEAU, MD
Contact
vanessa.bironneau@chu-poitiers.fr
05 49 44 34 49 ext. +33
Celine ABONNEAU, Project manager
Contact
celine.abonneau@chu-poitiers.fr
05 16 60 42 33 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion